Income statement
GBP
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 32M | 13M | 5M | 2M | 10M |
| Gross Profit | 15M | 4M | 2M | 539K | 9M |
| Operating Income | -23M | -31M | -41M | -20M | -2M |
| EBITDA | -21M | -30M | -25M | -19M | 1M |
| Net Income | -27M | -33M | -50M | -20M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.08
+0.00% today
1Y Change
+131.21%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shield Therapeutics plc (SHIEF) is a Healthcare stock with a market cap of $110.00M and listed on OTC. The stock last traded around $0.08 and up 131.2% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +57.9%, EPS growth of +31.7%, a dividend yield of 0.0%. What stands out right now is revenue +57.9%, EPS +31.7%, free cash flow +3.8% with operating margin -19.5% and ROIC -58.3%. Valuation is more restrained than many high-expectation growth names at price/sales 2.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SHIEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHIEF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHIEF Max Drawdown
-52.35%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SHIEF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$10.4M
+583.8% YoY
FY Net Income
-$3.6M
+81.8% YoY
Free Cash Flow
-$1.4M
+92.4% YoY
Revenue Growth
+57.9%
EPS Growth
+31.7%
Gross Margin
43.9%
Net Margin
-34.5%
Income statement
GBP
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 32M | 13M | 5M | 2M | 10M |
| Gross Profit | 15M | 4M | 2M | 539K | 9M |
| Operating Income | -23M | -31M | -41M | -20M | -2M |
| EBITDA | -21M | -30M | -25M | -19M | 1M |
| Net Income | -27M | -33M | -50M | -20M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7M | 14M | 3M | 12M | 3M |
| Total Assets | 57M | 49M | 22M | 44M | 33M |
| Total Liabilities | 59M | 34M | 17M | 3M | 2M |
| Shareholder Equity | -1M | 12M | 5M | 41M | 30M |
| Total Debt | 26M | 20M | 6M | 156K | 38K |
| Net Debt | 20M | 6M | 3M | -12M | -3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+91.6% YoY
Capital Expenditures
23K
+98.9% YoY
Free Cash Flow
1M
+92.4% YoY
Key ratios
Gross Margin
43.9%
Operating Margin
-19.5%
Net Margin
-34.5%
ROE
103.6%
Debt / Equity
-2.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.